Clinical Trial Update: A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ceralasertib as a standalone therapy and in combination with durvalumab in melanoma patients resistant to PD-(L)1 inhibitors, with tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Ceralasertib (ceralasertib)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-21